Article

Vioxx Association with Heart Attacks and Strokes Uncovered

A team of researchers uncovered the link between arthritis pain medication Vioxx and heart attacks and strokes.

A team of researchers uncovered the link between arthritis pain medication Vioxx and heart attacks and strokes. The results of the study are published in the Proceedings of the National Academy of Sciences.

The team featured scientists from the University of California, Davis and Peking University, China. By using metabolomic profiling, they analyzed murine (rodent) plasma and discovered Vioxx causes a dramatic increase in regulatory lipids that may play a role in contributing to heart attack and strokes associated with COX-2 inhibitors.

“This is a major breakthrough that can lead to a better medication for people suffering from acute pain,” said entomologist-chemist Bruce Hammock, a professor of entomology with a joint appointment at the UC Davis Cancer Center, in a press release.

The study demonstrated that 20-hydroxyeicosatetrasanoic acid, or 20-HETE, contributes to the Vioxx-mediated cardiovascular events. Vioxx was withdrawn from the market in September 2004. The researchers hope their findings will help promote further research into developing safer coxibs.

Related Videos
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
© 2024 MJH Life Sciences

All rights reserved.